Thonzylamine

Identification

Brand Names
Nasopen PE, Poly Hist Pd
Generic Name
Thonzylamine
DrugBank Accession Number
DB11235
Background

Thonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with Clofedanol or Phenylephrine for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 286.379
Monoisotopic: 286.179361344
Chemical Formula
C16H22N4O
Synonyms
  • neohetramine
  • Thonzylamine

Pharmacology

Indication

Thozylamine is indicated for use in the symptomatic control of allergic rhinitis or other upper respiratory allergic symptoms Label. It is typically a part of combination over the counter products.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatAllergiesCombination Product in combination with: Phenylephrine (DB00388)••• •••••••••
Used in combination to treatAllergiesCombination Product in combination with: Dextromethorphan (DB00514), Phenylephrine (DB00388)••• •••••••••
Used in combination to treatAllergiesCombination Product in combination with: Naphazoline (DB06711)•••••••••••••••••••• • •••••
Used in combination to treatCoughingCombination Product in combination with: Phenylephrine (DB00388), Dextromethorphan (DB00514)••• •••••••••
Used in combination to treatCoughingCombination Product in combination with: Clofedanol (DB04837)••• •••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Thonzylamine is a first-generation antihistamine. It antagonizes the action of histamine to relief allergic symptoms like nasal congestion, runny nose, itchy eyes, itchy nose and throat, and sneezing Label,1

Mechanism of action

Thonzylamine competes with histamine for binding to the H1 histamine receptor 1. Binding of histamine to this receptor stimulates vasodilation and increased vascular permeability leading to nasal congestion and runny nose 3. Histamine also produces itchiness by stimulating nerve endings which can result in sneezing. By blocking these effects, thonzylamine can reduce or eliminate symptoms of allergic rhinitis.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Humans
UMuscarinic acetylcholine receptor M1
antagonist
Humans
UMuscarinic acetylcholine receptor M2
antagonist
Humans
UMuscarinic acetylcholine receptor M3
antagonist
Humans
UMuscarinic acetylcholine receptor M4
antagonist
Humans
UMuscarinic acetylcholine receptor M5
antagonist
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Doses of up to 300 mg/day for up to 4 days have produces no observable toxic effects in humans 2. In a chronic toxicity study, rats were given up to 200 mg/kg/day orally for 91 days with no observable toxic effects 1.

Pathways
PathwayCategory
Thonzylamine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AclidiniumThe risk or severity of adverse effects can be increased when Thonzylamine is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Thonzylamine.
AlfentanilThe risk or severity of adverse effects can be increased when Thonzylamine is combined with Alfentanil.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Thonzylamine.
AmantadineThe risk or severity of adverse effects can be increased when Amantadine is combined with Thonzylamine.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Thonzylamine hydrochloride6K9YKD48Y463-56-9HRYJPHOTGFERGT-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
IRIDINA ANTISTAMINICOThonzylamine hydrochloride (1 mg/ml) + Naphazoline nitrate (0.8 MG/ML)Solution / dropsOphthalmicMontefarmaco Otc S.P.A.2014-07-082023-11-07Italy flag
Nasopen PEThonzylamine hydrochloride (50 mg/15mL) + Phenylephrine hydrochloride (10 mg/15mL)LiquidOralGM Pharmaceuticals, INC2012-10-03Not applicableUS flag
Poly Hist PDThonzylamine hydrochloride (6.25 mg/1mL) + Chlophedianol hydrochloride (6.25 mg/1mL)LiquidOralPoly Pharmaceuticals, Inc.2013-07-01Not applicableUS flag
Poly-Hist DMThonzylamine hydrochloride (25 mg/5mL) + Dextromethorphan hydrobromide monohydrate (10 mg/5mL) + Phenylephrine hydrochloride (5 mg/5mL)LiquidOralPoly Pharmaceuticals, Inc.2013-06-22Not applicableUS flag
TexaClear Kids Sinus ReliefThonzylamine hydrochloride (50 mg/30mL) + Phenylephrine hydrochloride (5 mg/30mL)LiquidOralGM Pharmaceuticals, INC2015-06-152019-01-16US flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Poly-Hist DMThonzylamine hydrochloride (25 mg/5mL) + Dextromethorphan hydrobromide monohydrate (10 mg/5mL) + Phenylephrine hydrochloride (5 mg/5mL)LiquidOralPoly Pharmaceuticals, Inc.2013-06-22Not applicableUS flag

Categories

ATC Codes
D04AA01 — ThonzylamineR06AC06 — ThonzylamineR01AC06 — Thonzylamine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Anisoles
Direct Parent
Anisoles
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Dialkylarylamines / Benzylamines / Aminopyrimidines and derivatives / Alkyl aryl ethers / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds
show 1 more
Substituents
Alkyl aryl ether / Amine / Aminopyrimidine / Anisole / Aromatic heteromonocyclic compound / Azacycle / Benzylamine / Dialkylarylamine / Ether / Heteroaromatic compound
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
R79646H5Z8
CAS number
91-85-0
InChI Key
GULNIHOSWFYMRN-UHFFFAOYSA-N
InChI
InChI=1S/C16H22N4O/c1-19(2)11-12-20(16-17-9-4-10-18-16)13-14-5-7-15(21-3)8-6-14/h4-10H,11-13H2,1-3H3
IUPAC Name
N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyrimidin-2-amine
SMILES
COC1=CC=C(CN(CCN(C)C)C2=NC=CC=N2)C=C1

References

General References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [Article]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [Article]
  3. Chapter 39: Histamine, Bradykinin, and Their Antagonists. (2018). In Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education. [ISBN:978-1-25-958473-2]
Human Metabolome Database
HMDB0240222
PubChem Compound
5457
PubChem Substance
347827947
ChemSpider
5258
RxNav
1360721
ChEBI
104017
ChEMBL
CHEMBL1623738
ZINC
ZINC000000057513
Wikipedia
Thonzylamine
FDA label
Download (190 KB)
MSDS
Download (82.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Solution / dropsOphthalmic
Solution / dropsOphthalmic
Solution / dropsConjunctival
LiquidOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)173-176Scudi JV, Reinhard JF, Dreyer NB. Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948;19(3):184-99.
water solubilityHighly SolubleScudi JV, Reinhard JF, Dreyer NB. Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948;19(3):184-99.
Predicted Properties
PropertyValueSource
Water Solubility0.733 mg/mLALOGPS
logP2.4ALOGPS
logP2.42Chemaxon
logS-2.6ALOGPS
pKa (Strongest Basic)8.62Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area41.49 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity86.19 m3·mol-1Chemaxon
Polarizability32.42 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0ab9-9450000000-72e6f4295340c602c154
GC-MS Spectrum - EI-BGC-MSsplash10-05fr-9720000000-8a7d4d036feab1e4ee54
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0090000000-49f05e1d16744b455b2c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-05n0-1970000000-8c03ee83ab4e7ea5aff3
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00dr-6590000000-c869069f29cd02886f28
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-06r7-4940000000-93c550679147efd82712
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00du-8920000000-3b2bd88123f6a3ee1823
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-05ai-1900000000-8ba8fcf5031a19af63de
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-182.1746133
predicted
DarkChem Lite v0.1.0
[M-H]-170.85757
predicted
DeepCCS 1.0 (2019)
[M+H]+182.8170133
predicted
DarkChem Lite v0.1.0
[M+H]+173.21556
predicted
DeepCCS 1.0 (2019)
[M+Na]+182.7976133
predicted
DarkChem Lite v0.1.0
[M+Na]+179.3087
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [Article]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [Article]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [Article]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [Article]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [Article]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [Article]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [Article]

Drug created at December 03, 2015 16:51 / Updated at February 21, 2021 18:53